Latest Industry Insights

The intricate and intertwined nature of the host‒microbiota connection has garnered increasing interest from the scientific community in recent years, due to its known role in the development and progression of various diseases. 4D pharma has leveraged growing knowledge in the field, by creating a novel class of medicines called live biotherapeutic products (LBPs).

In this interview, Jim Ross highlights several recent examples of how bioelectronic assays are helping to advance drug discovery for neurological diseases ranging from pediatric epilepsy to Burning Man Syndrome.

Emulate's chief scientific officer, Dr. Lorna Ewart, talks about inspiring a new generation of women in STEM.

Technology Networks interviewed Frank DeRosa, chief technology officer and head of research at the mRNA Center of Excellence, Sanofi, to discuss the “bright future” of mRNA platforms.

Technology Networks had the pleasure of interviewing Dr. Oliver Rinner, CEO at Biognosys, to learn more about some of the recent developments in proteomics, and discuss what the future could hold for the field.

Three-dimensional interactions across the genome can impact gene expression, and understanding these interactions could offer new insights into oncogenic mechanisms.

To learn more about the world's first Microhub – Mica – and some of the areas it could impact the most, Technology Networks spoke to James O’Brien, vice president life sciences at Leica Microsystems.

In this two-part interview series, Technology Networks explores some of the reasons behind the difficulties diagnosing and treating rare diseases, and finds out more about recent developments to improve options for patients.

In this two-part interview series, Technology Networks delves deeper into the diagnostic odyssey many rare disease patients face and explores current efforts to develop improved therapies for these patients.

Our ability to treat disorders of the body has advanced significantly in the 21st century. But that progress has not been matched by new therapies for psychiatric conditions. atai Life Sciences, a clinical-stage biopharmaceutical company, recently launched a new company that aims to correct that imbalance.